These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9890702)

  • 1. Pharmacoeconomic profile of taxanes in advanced ovarian cancer.
    Messori A; Trippoli S
    Anticancer Drugs; 1998 Nov; 9(10):909-16. PubMed ID: 9890702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A; Trippoli S; Becagli P; Tendi E
    Cancer; 1996 Dec; 78(11):2366-73. PubMed ID: 8941008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From randomised clinical trials to clinical practice : a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer.
    Limat S; Woronoff-Lemsi MC; Menat C; Madroszyk-Flandin A; Merrouche Y
    Pharmacoeconomics; 2004; 22(10):633-41. PubMed ID: 15244489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.
    McGuire W; Neugut AI; Arikian S; Doyle J; Dezii CM
    J Clin Oncol; 1997 Feb; 15(2):640-5. PubMed ID: 9053488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative pharmaco-economic analysis of docetaxel with cisplatin and cyclophosphamide with cisplatin in first-line chemotherapy of advanced ovarian cancer].
    Gorbunova VA; Khokhlova SV; Komarova BP; Orel NF; Besova NS
    Vopr Onkol; 2002; 48(6):695-9. PubMed ID: 12530266
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective.
    Berger K; Fischer T; Szucs TD
    Eur J Cancer; 1998 Nov; 34(12):1894-901. PubMed ID: 10023312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacoeconomics of cancer therapies.
    Bishop JF; Macarounas-Kirchman K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is paclitaxel and cisplatin a cost-effective first-line therapy for advance ovarian carcinoma?
    Covens A; Boucher S; Roche K; Macdonald M; Pettitt D; Jolain B; Souetre E; Rivière M
    Cancer; 1996 May; 77(10):2086-91. PubMed ID: 8640674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.
    Ortega A; Dranitsaris G; Sturgeon J; Sutherland H; Oza A
    Gynecol Oncol; 1997 Sep; 66(3):454-63. PubMed ID: 9299261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
    Messori A; Cecchi M; Becagli P; Trippoli S
    Cancer; 1997 Jun; 79(11):2264-6. PubMed ID: 9179077
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.
    Elit LM; Gafni A; Levine MN
    J Clin Oncol; 1997 Feb; 15(2):632-9. PubMed ID: 9053487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
    Neymark N; Gorlia T; Adriaenssen I; Baron B; Piccart M
    Pharmacoeconomics; 2002; 20(7):485-97. PubMed ID: 12093304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
    Messori A; Trippoli S; Becagli P; Tendi E
    Anticancer Drugs; 1998 Jul; 9(6):491-502. PubMed ID: 9877236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.
    Havrilesky LJ; Garfield CF; Barnett JC; Cohn DE
    Gynecol Oncol; 2012 Jun; 125(3):631-4. PubMed ID: 22446408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.